Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917
CS-917 (MB06322) is a selective small compound inhibitor of fructose 1,6-bisphosphatase (FBPase), which is expected to be a novel drug for the treatment of type 2 diabetes by inhibiting gluconeogenesis. CS-917 is a bisamidate prodrug and activation of CS-917 requires a two-step enzyme catalyzed reac...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley & Sons, Ltd
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492754/ |